# Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06706713/  
OnCo record `nct06706713` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BEBT-109 Capsule in non-small-cell lung cancer, run by BeBetter Med Inc, now recruiting.

## Summary

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06706713 by BeBetter Med Inc, with 200 participants planned, started 2022-04-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: BEBT-109 Capsule.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06706713
- Phase: 2
- Setting: An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: BeBetter Med Inc
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06706713: https://clinicaltrials.gov/study/NCT06706713

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [BeBetter Med](https://onco.cc/companies/bebetter-med/)

---
JSON: https://onco.cc/api/v1/entities/nct06706713.json